Literature DB >> 19824893

Synthesis, kinetic characterization and metabolism of diastereomeric 2-(1-(4-phenoxyphenylsulfonyl)ethyl)thiiranes as potent gelatinase and MT1-MMP inhibitors.

Major Gooyit1, Mijoon Lee, Dusan Hesek, Bill Boggess, Allen G Oliver, Rafael Fridman, Shahriar Mobashery, Mayland Chang.   

Abstract

Gelatinases (MMP-2 and MMP-9) have been implicated in a number of pathological conditions, including cancer and cardiovascular disease. Hence, small molecule inhibitors of these enzymes are highly sought for use as potential therapeutic agents. 2-(4-Phenoxyphenylsulfonylmethyl)thiirane (SB-3CT) has previously been demonstrated to be a potent and selective inhibitor of gelatinases, however, it is rapidly metabolized because of oxidation at the para position of the phenoxy ring and at the alpha-position to the sulfonyl group. alpha-Methyl variants of SB-3CT were conceived to improve metabolic stability and as mechanistic probes. We describe herein the synthesis and evaluation of these structural variants as potent inhibitors of gelatinases. Two (compounds 5b and 5d) among the four synthetic stereoisomers were found to exhibit slow-binding inhibition of gelatinases and MMP-14 (MT1-MMP), which is a hallmark of the mechanism of this class of inhibitors. The ability of these compounds to inhibit MMP-2, MMP-9, and MMP-14 could target cancer tissues more effectively. Metabolism of the newly synthesized inhibitors showed that both oxidation at the alpha-position to the sulfonyl group and oxidation at the para position of the terminal phenyl ring were prevented. Instead oxidation on the thiirane sulfur is the only biotransformation pathway observed for these gelatinase inhibitors.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19824893      PMCID: PMC2901852          DOI: 10.1111/j.1747-0285.2009.00898.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  23 in total

1.  Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix.

Authors:  Kevin B Hotary; Edward D Allen; Peter C Brooks; Nabanita S Datta; Michael W Long; Stephen J Weiss
Journal:  Cell       Date:  2003-07-11       Impact factor: 41.582

2.  Angiogenesis inhibitors: motivators of metastasis?

Authors:  Patricia S Steeg
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

Review 3.  Extracellular matrix remodelling: the role of matrix metalloproteinases.

Authors:  Ivan Stamenkovic
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

4.  A convenient synthesis of a selective gelatinase inhibitor as an antimetastatic agent.

Authors:  In Taek Lim; Stephen Brown; Shahriar Mobashery
Journal:  J Org Chem       Date:  2004-05-14       Impact factor: 4.354

Review 5.  The regulation of neovascularization of matrix metalloproteinases and their inhibitors.

Authors:  M A Moses
Journal:  Stem Cells       Date:  1997       Impact factor: 6.277

Review 6.  Human endothelial gelatinases and angiogenesis.

Authors:  M Nguyen; J Arkell; C J Jackson
Journal:  Int J Biochem Cell Biol       Date:  2001-10       Impact factor: 5.085

Review 7.  Matrix metalloproteinases and metastasis.

Authors:  D E Kleiner; W G Stetler-Stevenson
Journal:  Cancer Chemother Pharmacol       Date:  1999       Impact factor: 3.333

8.  Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases.

Authors:  M Margarida Bernardo; Stephen Brown; Zhi-Hong Li; Rafael Fridman; Shahriar Mobashery
Journal:  J Biol Chem       Date:  2002-01-14       Impact factor: 5.157

Review 9.  Tumorigenesis and the angiogenic switch.

Authors:  Gabriele Bergers; Laura E Benjamin
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

10.  A potent gelatinase inhibitor with anti-tumor-invasive activity and its metabolic disposition.

Authors:  Mijoon Lee; Giuseppe Celenza; Bill Boggess; Jennifer Blase; Qicun Shi; Marta Toth; M Margarida Bernardo; William R Wolter; Mark A Suckow; Dusan Hesek; Bruce C Noll; Rafael Fridman; Shahriar Mobashery; Mayland Chang
Journal:  Chem Biol Drug Des       Date:  2009-02       Impact factor: 2.817

View more
  6 in total

1.  O-phenyl carbamate and phenyl urea thiiranes as selective matrix metalloproteinase-2 inhibitors that cross the blood-brain barrier.

Authors:  Major Gooyit; Wei Song; Kiran V Mahasenan; Katerina Lichtenwalter; Mark A Suckow; Valerie A Schroeder; William R Wolter; Shahriar Mobashery; Mayland Chang
Journal:  J Med Chem       Date:  2013-10-08       Impact factor: 7.446

2.  Selective gelatinase inhibitor neuroprotective agents cross the blood-brain barrier.

Authors:  Major Gooyit; Mark A Suckow; Valerie A Schroeder; William R Wolter; Shahriar Mobashery; Mayland Chang
Journal:  ACS Chem Neurosci       Date:  2012-07-30       Impact factor: 4.418

3.  Selective water-soluble gelatinase inhibitor prodrugs.

Authors:  Major Gooyit; Mijoon Lee; Valerie A Schroeder; Masahiro Ikejiri; Mark A Suckow; Shahriar Mobashery; Mayland Chang
Journal:  J Med Chem       Date:  2011-09-06       Impact factor: 7.446

Review 4.  Drug-target residence time: critical information for lead optimization.

Authors:  Hao Lu; Peter J Tonge
Journal:  Curr Opin Chem Biol       Date:  2010-07-19       Impact factor: 8.822

Review 5.  Role of matrix metalloproteinases and therapeutic benefits of their inhibition in spinal cord injury.

Authors:  Haoqian Zhang; Mayland Chang; Christopher N Hansen; D Michele Basso; Linda J Noble-Haeusslein
Journal:  Neurotherapeutics       Date:  2011-04       Impact factor: 7.620

Review 6.  Mechanisms of Action of Novel Drugs Targeting Angiogenesis-Promoting Matrix Metalloproteinases.

Authors:  Gregg B Fields
Journal:  Front Immunol       Date:  2019-06-04       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.